VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

VJVirtual | Enasidenib for IDH2-mutated MDS

Valeria Santini, MD, University of Florence, Florence, Italy, gives us a round-up of some of the exciting trials currently taking place in the myelodysplastic syndromes (MDS) space. Specifically, Dr Santini outlined the use of enasidenib for IDH2-mutated MDS. This interview was filmed via an online conference call with VJHemOnc.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter